Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

Indication Sought for Breakthrough Pain Associated with Chronic Pain

Conditions in Patients Who are Already Taking Opioid Medications

Around-the-Clock

FRAZER, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid tolerant patients with chronic pain conditions. Breakthrough pain is characterized by its rapid onset, moderate- to-severe intensity, and relatively short duration. According to a study published in the August 2006 issue of The Journal of Pain, up to 74 percent of patients with non-cancer chronic pain conditions treated for persistent pain, such as chronic low back and chronic neuropathic pain, will experience breakthrough pain. Currently FENTORA is approved for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent pain.

"The clinical trials supporting this submission mark the first time a pain medication has been evaluated as a treatment for breakthrough pain associated with serious chronic pain conditions other than cancer," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We look forward to working with FDA to broaden the use of FENTORA to opioid tolerant patients with unresolved debilitating breakthrough pain."

The FENTORA sNDA includes data from three randomized, placebo-controlled clinical trials and one long-term open-label safety study with a total of 941 opioid tolerant patients. The patients in the FENTORA sNDA trials were treated for up to 18 months and had a broad range of underlying chronic pain conditions, including chronic low back and chronic neuropathic pain. In the randomiz
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... as the supplier of bio-succinic acid used to ... for textile applications that Bayer MaterialScience has begun ... IMPRANIL ® eco, a series of bio-based ... as high as 65%.  IMPRANIL ® eco ...
(Date:4/24/2015)... 2015 PAREXEL International Corporation (NASDAQ: PRXL ... that Partnerships in Clinical Trials named PAREXEL,s Drew ... Innovator of the Year.  The honor recognizes Mr. Garty,s ... Perceptive MyTrials ® Data-Driven Monitoring solution. ... 2015 Partnership Awards in Boston , ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 The ... intends to conduct a groundbreaking pilot study to ... be reversed in as little as three to ... of metabolic and nutritional medicine—will aggressively target and ... and destroy our aging brain. These include oxidative ...
(Date:4/23/2015)... April 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... its first quarter 2015 results before the Nasdaq market ... host a live conference call and webcast to discuss its ... April 30, 2015 at 8:00 a.m. Eastern Time (5:00 ... live conference call by dialing 866-952-1906 (US) or 785-424-1825 ...
Breaking Biology Technology:Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2
... 12, 2011 Water Street Healthcare Partners , ... care, announced today that Scott Garrett has joined the ... former chairman, president and chief executive officer of Beckman ... years of experience leading health care businesses ranging from ...
... WORTH, Texas, April 12, 2011 Wound Management Technologies, ... wound care solutions, today announced that the Company has ... McAllen, Texas to distribute CellerateRX® gel products in select ... the agreement calls for 1st year sales of at ...
... 12, 2011 Dr. Fresh®, Inc., maker of the ... Facebook fundraising initiative to raise awareness and funds for ... 12, 2011, the company will donate $1 for every ... to $2500, to Smile Train.  The organization provides life-changing ...
Cached Biology Technology:Scott Garrett Joins Water Street Healthcare Partners 2Scott Garrett Joins Water Street Healthcare Partners 3WNDM Signs $1.5 M Multiyear Regional Distribution Agreement 2WNDM Signs $1.5 M Multiyear Regional Distribution Agreement 3FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train 2
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... major food source for much of the world, rice is one ... from disease has become, in part, the task of a group ... State University. The researchers are looking at two bacterial diseases ... is caused by a bacterium called Xanthomonas oryzae pathovar oryzae ...
... N.Y. (Wednesday, April 1, 2009) Along with new ... home to an in-depth library of basic laboratory methods. ... of these standard techniques. From molecular biology researchers ... is the commonly used method for nucleic acid amplification. ...
... (SACRAMENTO, Calif.) New research from UC Davis Cancer Center ... ingredient that allows breast cancer to spread to other organs ... April 1 issue of Cancer Research , is one ... the disease. Kermit Carraway, senior author of the study, ...
Cached Biology News:Researchers examine bacterial rice diseases, search for genetic solutions 2Basic guides to PCR, labeling neurons featured in Cold Spring Harbor Protocols 2UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs 2
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
... (PPAR) is a member of a ... factors that heterodimerize with retinoic acid-like ... the regulation of glucose and lipid ... of anti-diabetic agents called thiazolidinediones (TZD) ...
... used for the identification of potential biomarkers in ... other diseases. Due to the fact that urine ... provides an attractive alternative to blood plasma as ... Urine Protein Concentration Micro Kit provides a ...
Biology Products: